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Mohs Patient Demographics: 
A quality improvement study analyzing patient demographics and access to Mohs Surgery for 
basal cell carcinoma and squamous cell carcinoma
REFERENCES
Table 1: Patient Characteristics • Compared to other publications, shorter surgical waiting times
– average : 50 days between biopsy and surgery
– Vs. 70, 90, and 133 days .2,8,9
• No significant association between demographic factors and 
NMSC surgical wait times
– no correlation between age, sex, or insurance payor with surgical 
delay 
– unlike the results of many articles focused on melanoma
• delays with older age and female gender
• Medicaid patients compared to patients with private 
insurance and for nonwhite patients.7
• Place of Biopsy and Healthcare system coordination
– Biopsy inside network 
– Future studies should focus on evaluating the workflow to identify 
the cause of delays and actions that can be taken to streamline this 
process.
• Non-dermatologist specialty surgeon performed the closure 
causing delays
– difficulty coordinating the schedules of the two surgeons involved 
– Lott et al. found that for melanomas, the minimum probability of 
surgical delay over 45 days occurred when a dermatologist 
performed both the biopsy and the excision, whereas the maximum 
probability occurred when a dermatologist performed the biopsy 
followed by excision by a primary care physician.5
– Improving communication between specialties or reserving total care 
of NMSCs for dermatologists, when feasible, may decrease surgical 
wait times. 
• A retrospective chart review of 1020 patients who 
underwent Mohs micrographic for SCC or BCC over 12 
months from October 1, 2016 to September 30, 2017. 
• Patient records and the following information was gathered:
• referring provider 
• biopsy location 
• date of biopsy, age of patient 
• gender of patient
• date of Moh’s surgery
• type of insurance (private, Medicare, Medicare 
Advantage, Medicaid, VA, Charity Care) 
• type of cancer
• pre-operative lesion size
• post-operative size
• repair (Moh’s, plastic surgery or Ear, Nose and 
Throat)
• date of referral
• Repeated measures mixed models : estimate the 
association between time from biopsy and referral to surgery 
– post-surgical size and change in size were fit as outcome 
measures
• Pearson correlation coefficient assess the relationship 
– size of the Mohs defect and the length of the interval from 
biopsy/referral. 
– power to detect an effect size of 0.15, with power of 80% and a 






• #1 cancer in the US : Non-melanoma skin cancer (NMSC), 
squamous cell carcinoma (SCC) and basal cell carcinoma 
(BCC)
• Mohs surgery is used to treat skin cancer
– thin layers of cancer-containing skin are progressively removed
– preserves normal tissue, a five-year recurrence-free survival rate 
of 99%.1
• Risk of metastasis and mortality is low, but NMSCs destroy 
tissue.2
• Wait times in the US have been increasing
• longer time, means further spread leading to larger surgery and 
defect
• factors that lengthen surgical delay for melanoma patients.3,4,5,6,7
• type of insurance a patient effects the time from biopsy to definitive 
treatment.2
• one study : type of insurance affects the quality of care for a variety of 
ailments within the same hospital system.3 
Are there geographic, demographic or healthcare related 
factors that influence time to Mohs surgery and thus local 
destruction/metastasis ?
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• Project aimed to identify patient’s barriers of care 
when seeking Moh’s surgery for NMSC.  
• A retrospective chart review of Moh’s surgical 
patients found that surgical delay was not 
associated with age, sex, or insurance payor. 
• SELECT principles such as barriers to care and 
communication between specialties 
• In the future, this project may be expanded by 
looking at social and psychosocial limitations that 
may have influenced the timeliness of pursuit of 
Moh’s micrographic surgery in the treatment of 
NMSC. 
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